

Practitioner's Docket No. MPI99-193CN2M

PATENT

\$

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Kapeller-Libermann, Rosana et al.		
Application No.:	10/767,308	Group No.:	1635
Filed:	January 29, 2004	Examiner:	Schnizer, Richard A.
For:	2786, A NOVEL HUMAN AMINOPEPTIDASE		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DEPOSIT DECLARATION

Sir:

I, Mario Cloutier, hereby declare that:

1. I am an agent of record in the above-identified patent application.
2. A plasmid containing a human cDNA insert for gene 2786 (p2786), described in the above-identified patent application, was deposited with the American Type Culture

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee" Mailing Label No.

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: January 9, 2006

Sean Hunziker

(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

2. A plasmid containing a human cDNA insert for gene 2786 (p2786), described in the above-identified patent application, was deposited with the American Type Culture Collection (ATCC®), 10801 University Boulevard, Manassas, VA 20110-2209, on December 15, 2000 under the terms of the Budapest Treaty and assigned ATCC® Accession Number PTA-2811.

3. Upon granting of a patent on the above-identified patent application, all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed and the deposit will be replaced if viable samples cannot be dispensed by the repository.

I hereby declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the instant patent application or any patent issued thereon.

January 9, 2006

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By



Mario Cloutier


Registration No. 57,225

40 Landsdowne Street

Cambridge, MA 02139

Telephone - 617-577-3522

Facsimile - 617-551-8820



Practitioner's Docket No. **MPI99-193CN2M**

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Rosana Kapeller-Libermann, et al.		
Application No.:	10/767,308	Group No.:	1635
Filed:	January 29, 2004	Examiner:	Schnizer, Richard A.
For:	2786, A NOVEL HUMAN AMINOPEPTIDASE		

Mail Stop Amendment

Confirmation No. 5472

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL

1. Transmitted herewith for this application is/are:
 - a. This Transmittal (3 pages – in duplicate);
 - b. Amendment and Response (14 pages);
 - c. Submission of Substitute Sequence Listing (4 pages);
 - d. Paper Copy of Substitute Sequence Listing (7 pages);
 - e. Diskette containing the Substitute Sequence Listing;
 - f. Deposit Declaration (2 pages);
 - g. Transmittal of Information Disclosure Statement (2 pages – in duplicate);
 - h. Information Disclosure Statement (2 pages);
 - i. Form PTO/SB/08B (substitute for Form PTO-1449) (2 pages);
 - j. Copy of References cited in Information Disclosure Statement (Citation Nos. D1-D9);
 - k. Power of Attorney and Correspondence Address Indication Form (1 page);
 - l. Statement under 37 CFR 3.73(b) (1 page);
 - m. Copy of Notice of Recordation, Recordation Form Cover Sheet, and executed Assignment (12 pages); and
 - n. Return postcard.

STATUS

2. Applicant is other than a small entity.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Addressee"
Mailing Label No. _____

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.


Signature

Sean Hunziker

(type or print name of person certifying)

Date: January 9, 2006

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

PETITION FOR EXTENSION OF TIME

2. The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply. Applicant petitions for an extension of time under 37 C.F.R. 1.136 (fees: 37 C.F.R. 1.17(a)(1)-(3)) for a one month extension:

Fee: \$120.00

Extension fee due with this request \$120.00

If an additional extension of time is required, please consider this a petition therefor.

FEE FOR CLAIMS

4. The fee for claims (37 C.F.R. 1.16(b)-(d)) has been calculated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)		OTHER THAN A SMALL ENTITY	
Claims Remaining After Amendment		Highest No. Previously Paid For		Present Extra		Rate	Addit. Fee
Total	9	Minus	12	=	0	\$50.00 =	\$0.00
Indep.	5	Minus	5	=	0	\$200.00 =	\$0.00
Multiple Dependent Claims	no		no			\$360.00 =	\$0.00
						Total Addit. Fee	\$0.00

Total additional fee for claims required \$0.00

FEE PAYMENT

5. Charge Account No. 501668 the sum of \$120.00 (which includes the \$120.00 extension fee). A duplicate of this transmittal is attached.

Practitioner's Docket No. MPI99-193CN2M

FEE DEFICIENCY

6. If any additional extension and/or fee is required, charge Account No. 501668.
If any additional fee for claims is required, charge Account No. 501668.

7. Correspondence Address

Direct all future correspondence to:

Customer Number 30405

OR

Intellectual Property Department
MILLENNIUM PHARMACEUTICALS, INC.
40 Landsdowne Street
Cambridge, MA 02139

January 9, 2006

MILLENNIUM PHARMACEUTICALS, INC.

By


Mario Cloutier

Registration No. 57,225

40 Landsdowne Street

Cambridge, MA 02139

Telephone - 617-577-3522

Facsimile - 617-551-8820